Related references
Note: Only part of the references are listed.Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency
Fang Zhao et al.
CANCER RESEARCH (2016)
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes
Katy J. McCann et al.
CLINICAL CANCER RESEARCH (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
Wei Xue et al.
ONCOTARGET (2016)
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
Wei Xue et al.
ONCOIMMUNOLOGY (2016)
Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
Maurizio Zanetti
JOURNAL OF IMMUNOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice
Jaimy M. S. Saif et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
High-Avidity T Cells Are Preferentially Tolerized in the Tumor Microenvironment
Ziqiang Zhu et al.
CANCER RESEARCH (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
Monica Bernal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
Victoria A. Brentville et al.
PLOS ONE (2012)
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hemon et al.
JOURNAL OF IMMUNOLOGY (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells
Victoria A. Pudney et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Electroporation for DNA immunization: clinical application
Sylvia van Drunen Littel-van den Hurk et al.
EXPERT REVIEW OF VACCINES (2010)
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Ying Xie et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Antibodies designed as effective cancer vaccines
R. L. Metheringham et al.
MABS (2009)
Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration
Pieranna Chiarella et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
Jeffrey A. Sosman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Constitutive and IFNγ-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region
Nienke van der Stoep et al.
MOLECULAR IMMUNOLOGY (2007)
Pathologic expression of MHC class II is driven by mitogen-activated protein kinases
Isabelle Martins et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Pre-existing immunity to tyrosinase-related protein (TRIP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy
HT Khong et al.
JOURNAL OF IMMUNOLOGY (2002)
In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity
C Sedlik et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
